We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... and an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, long ...

Novo Nordisk A/S is a global healthcare company engaged in diabetes ... The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone ...

About Novo Nordisk A/S (ADR) and Amgen Inc Novo Nordisk A/S is a ... The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

is a biotech company with immense growth potential. Currently, the company has an investigational obesity drug in trials. If the drug succeeds, it could offer robust competition to major ...

Treatments are limited – doctors can prescribe painkillers and use hormone therapy to slow growth ... It also has backing from investors including Novo Nordisk's investment vehicle, Novo Seeds.

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...